Actively Recruiting
Phase II Study of Tislelizumab Combined With Radiotherapy and Gemcitabine-Platinum Chemotherapy for Borderline or Unresectable Hilar Cholangiocarcinoma
Led by Jinbo Yue · Updated on 2026-10-15
38
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combined neoadjuvant therapy approach for patients with borderline resectable or unresectable hilar cholangiocarcinoma, a rare and aggressive bile duct cancer. This phase II, single-arm, prospective clinical trial studies the safety and effectiveness of stereotactic body radiotherapy SBRT followed by combined chemotherapy and immunotherapy using gemcitabine, cisplatin or oxaliplatin, and tislelizumab. The goal is to improve tumor resectability and overall survival for patients with limited surgical options. Participants will first receive SBRT targeted to the tumor and metastatic lymph nodes using either 5 Gy over 5 to 8 fractions or 4 Gy over 15 fractions. After radiotherapy, they will undergo six cycles of combination therapy every 21 days, including intravenous tislelizumab, gemcitabine, and either cisplatin or oxaliplatin, depending on their condition. Following three cycles, patients will be re-evaluated for surgery. Those eligible for resection may have surgery and receive additional postoperative therapy. Patients with unresectable disease will continue systemic therapy for three more cycles and may receive maintenance tislelizumab for up to one year. During the study, participants will have regular assessments including imaging and clinical evaluations to monitor tumor response, surgical feasibility, and safety. Researchers will measure overall survival as the primary outcome over up to 36 months and secondary outcomes such as surgical success rate, pathological response, progression-free survival, local tumor control, and treatment-related side effects. The study involves follow-up visits to assess these outcomes and ensure participant safety throughout and after therapy.
CONDITIONS
Brief Title
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Research Team
J
Jinbo Yue
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here